



Clinical trial results:

A Phase 1b/2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination With the Poly (Adenosine Diphosphate [ADP]-Ribose)

Summary

EudraCT number	2017-001509-33
Trial protocol	BE HU DK GB
Global end of trial date	04 January 2023

Results information

Result version number	v1 (current)
This version publication date	14 September 2023
First version publication date	14 September 2023

Trial information

Trial identification

Sponsor protocol code	B9991025
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03330405
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 June 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	04 January 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess the dose limiting toxicity (DLT) rate of avelumab in combination with talazoparib in subjects with locally advanced or metastatic solid tumors in order to select the recommended Phase 2 dose (RP2D) of talazoparib for the combination, and to assess objective response rate (ORR) of avelumab in combination with talazoparib, as assessed by the investigator, per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) in subjects with locally advanced or metastatic solid tumors and per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) in subjects with metastatic castration resistant prostate cancer (mCRPC).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 October 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	62 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 10
Country: Number of subjects enrolled	Belgium: 7
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Denmark: 11
Country: Number of subjects enrolled	Hungary: 9
Country: Number of subjects enrolled	Korea, Republic of: 10
Country: Number of subjects enrolled	Russian Federation: 43
Country: Number of subjects enrolled	United Kingdom: 9
Country: Number of subjects enrolled	United States: 117
Worldwide total number of subjects	223
EEA total number of subjects	27

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	108
From 65 to 84 years	112
85 years and over	3

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 2 phases: Phase 1b (talazoparib dose level cohorts) and Phase 2 (expansion phase). Phase 2 was conducted at the highest dose level of talazoparib which was determined safe for subjects in Phase 1b.

Pre-assignment

Screening details:

Phase 1b: 12 subjects were enrolled and assigned to study treatment. Phase 2: 211 subjects were enrolled and assigned to study treatment.

Period 1

Period 1 title	Overall Study (Treatment Phase) (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD

Arm description:

Subjects with locally advanced or metastatic solid tumors were treated with talazoparib 1.0 mg orally once daily (QD) in combination with avelumab 800 mg intravenously (IV) every 2 weeks (Q2W) for a maximum of 246.3 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Arm title	Phase 2: Cohort A1 (NSCLC)
------------------	----------------------------

Arm description:

Subjects with locally advanced (primary or recurrent) or metastatic non-small cell lung cancer (NSCLC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 183.6 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort A2 (NSCLC DDR+)
------------------	---------------------------------

Arm description:

Subjects with locally advanced (primary or recurrent) or metastatic NSCLC with DNA damage repair positive (DDR+) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 173.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort B1 (TNBC)
------------------	---------------------------

Arm description:

Subjects with locally advanced (primary or recurrent) or triple-negative breast cancer (TNBC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 93.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.	
Arm title	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Arm description:	
Subjects with locally advanced (primary or recurrent) or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 180.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects received talazoparib 1 mg orally QD.	
Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.	
Arm title	Phase 2: Cohort C1 (OVC)
Arm description:	
Subjects with locally advanced (primary or recurrent) or metastatic ovarian cancer (OVC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 161.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Subjects received talazoparib 1 mg orally QD.	
Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.	
Arm title	Phase 2: Cohort C2 (OVC BRCA-mutated)

Arm description:

Subjects with locally advanced (primary or recurrent) or metastatic OVC with germline or somatic BRCA1 or BRCA2 gene defect were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 144.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort D (UC)
------------------	------------------------

Arm description:

Subjects with locally advanced (primary or recurrent) or metastatic urothelial cancer (UC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 164.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort E1 (mCRPC)
------------------	----------------------------

Arm description:

Subjects with metastatic castration-resistant prostate cancer (mCRPC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 54.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort E2 (mCRPC DDR+)
------------------	---------------------------------

Arm description:

Subjects with mCRPC with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 74.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Arm title	Phase 2: Cohort F (BRCA/ATM-mutated)
------------------	--------------------------------------

Arm description:

Subjects with locally advanced (primary or recurrent) or metastatic solid tumors, independent of tissue of origin, with previously identified pathogenic, or likely pathogenic, germline or somatic defects in BRCA1, BRCA2, or ATM genes were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 49.9 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Arm type	Experimental
Investigational medicinal product name	Talazoparib 1 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Subjects received talazoparib 1 mg orally QD.

Investigational medicinal product name	Avelumab 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received avelumab 800 mg as an IV infusion over 1 hour every 2 weeks on Day 1 and Day 15 of each 28-day cycle.

Number of subjects in period 1	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)
Started	12	42	5
Completed	0	0	0
Not completed	12	42	5
Consent withdrawn by subject	1	4	-
Physician decision	-	-	-
Global deterioration of health status	2	3	-
Adverse event, non-fatal	-	1	-
Death	-	4	-
Unspecified	1	3	1
Progressive disease	8	27	4

Number of subjects in period 1	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2-DDR+)	Phase 2: Cohort C1 (OVC)
Started	22	23	20
Completed	0	0	0
Not completed	22	23	20
Consent withdrawn by subject	1	1	1
Physician decision	-	-	-
Global deterioration of health status	2	3	3
Adverse event, non-fatal	1	1	1
Death	-	-	1
Unspecified	-	2	-
Progressive disease	18	16	14

Number of subjects in period 1	Phase 2: Cohort C2 (OVC BRCA-mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
Started	11	40	21
Completed	0	0	0
Not completed	11	40	21
Consent withdrawn by subject	-	2	2
Physician decision	-	1	-

Global deterioration of health status	-	2	8
Adverse event, non-fatal	3	4	2
Death	-	2	-
Unspecified	1	-	-
Progressive disease	7	29	9

Number of subjects in period 1	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)
Started	18	9
Completed	0	0
Not completed	18	9
Consent withdrawn by subject	1	1
Physician decision	-	-
Global deterioration of health status	4	1
Adverse event, non-fatal	2	2
Death	-	-
Unspecified	-	-
Progressive disease	11	5

Baseline characteristics

Reporting groups

Reporting group title	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD
Reporting group description: Subjects with locally advanced or metastatic solid tumors were treated with talazoparib 1.0 mg orally once daily (QD) in combination with avelumab 800 mg intravenously (IV) every 2 weeks (Q2W) for a maximum of 246.3 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort A1 (NSCLC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic non-small cell lung cancer (NSCLC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 183.6 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort A2 (NSCLC DDR+)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic NSCLC with DNA damage repair positive (DDR+) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 173.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort B1 (TNBC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or triple-negative breast cancer (TNBC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 93.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 180.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort C1 (OVC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic ovarian cancer (OVC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 161.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort C2 (OVC BRCA-mutated)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic OVC with germline or somatic BRCA1 or BRCA2 gene defect were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 144.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort D (UC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic urothelial cancer (UC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 164.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort E1 (mCRPC)
Reporting group description: Subjects with metastatic castration-resistant prostate cancer (mCRPC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 54.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort E2 (mCRPC DDR+)

Reporting group description:

Subjects with mCRPC with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 74.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Phase 2: Cohort F (BRCA/ATM-mutated)
-----------------------	--------------------------------------

Reporting group description:

Subjects with locally advanced (primary or recurrent) or metastatic solid tumors, independent of tissue of origin, with previously identified pathogenic, or likely pathogenic, germline or somatic defects in BRCA1, BRCA2, or ATM genes were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 49.9 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)
Number of subjects	12	42	5
Age Categorical Units: Subjects			
<65 years	6	15	4
65 - <75 years	5	19	1
75 - <85 years	1	7	0
>= 85 years	0	1	0
Age Continuous			
The reporting group of "Phase 2: All Cohorts Combined" was a combination of all Phase 2 subjects. No analysis of this combined group was planned, therefore "0" was added.			
Units: years			
arithmetic mean	62.67	67.00	59.60
standard deviation	± 9.49	± 9.37	± 7.40
Sex: Female, Male Units: Subjects			
Female	3	9	2
Male	9	33	3
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	12	39	5
Not reported	0	3	0
Race/Ethnicity, Customized Units: Subjects			
Black or African American	3	1	0
American Indian or Alaska Native	0	0	0
Asian	0	5	0
Native Hawaiian or Other Pacific Islander	0	0	1
White	9	34	4
Not reported	0	2	0
Geographic Region Units: Subjects			
North America	12	9	3
Western Europe	0	10	2
Eastern Europe	0	19	0
Australasia	0	0	0

Asia	0	4	0
ECOG Performance Status			
ECOG=Eastern Cooperative Oncology Group. Score 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work or office work.			
Units: Subjects			
ECOG Score = 0	4	5	1
ECOG Score = 1	8	37	4

Reporting group values	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)	Phase 2: Cohort C1 (OVC)
Number of subjects	22	23	20
Age Categorical			
Units: Subjects			
<65 years	15	17	12
65 - <75 years	6	3	5
75 - <85 years	1	3	3
>= 85 years	0	0	0
Age Continuous			
The reporting group of "Phase 2: All Cohorts Combined" was a combination of all Phase 2 subjects. No analysis of this combined group was planned, therefore "0" was added.			
Units: years			
arithmetic mean	56.18	53.83	62.65
standard deviation	± 12.49	± 14.08	± 10.66
Sex: Female, Male			
Units: Subjects			
Female	22	22	20
Male	0	1	0
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	1	0
Not Hispanic or Latino	19	21	18
Not reported	3	1	2
Race/Ethnicity, Customized			
Units: Subjects			
Black or African American	0	0	0
American Indian or Alaska Native	0	1	0
Asian	1	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
White	20	17	18
Not reported	1	4	2
Geographic Region			
Units: Subjects			
North America	14	15	10
Western Europe	0	1	2
Eastern Europe	6	4	5
Australasia	2	2	3
Asia	0	1	0
ECOG Performance Status			
ECOG=Eastern Cooperative Oncology Group. Score 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work or office work.			

Units: Subjects			
ECOG Score = 0	12	12	9
ECOG Score = 1	10	11	11

Reporting group values	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
Number of subjects	11	40	21
Age Categorical			
Units: Subjects			
<65 years	7	16	8
65 - <75 years	3	16	12
75 - <85 years	1	7	1
>= 85 years	0	1	0
Age Continuous			
The reporting group of "Phase 2: All Cohorts Combined" was a combination of all Phase 2 subjects. No analysis of this combined group was planned, therefore "0" was added.			
Units: years			
arithmetic mean	61.36	65.73	63.71
standard deviation	± 9.24	± 9.19	± 7.40
Sex: Female, Male			
Units: Subjects			
Female	11	14	0
Male	0	26	21
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	2	3
Not Hispanic or Latino	11	38	11
Not reported	0	0	7
Race/Ethnicity, Customized			
Units: Subjects			
Black or African American	2	1	5
American Indian or Alaska Native	0	0	0
Asian	3	2	1
Native Hawaiian or Other Pacific Islander	0	0	0
White	6	36	12
Not reported	0	1	3
Geographic Region			
Units: Subjects			
North America	7	15	20
Western Europe	1	5	1
Eastern Europe	1	16	0
Australasia	0	2	0
Asia	2	2	0
ECOG Performance Status			
ECOG=Eastern Cooperative Oncology Group. Score 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work or office work.			
Units: Subjects			
ECOG Score = 0	8	16	4
ECOG Score = 1	3	24	17

Reporting group values	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)	Total
Number of subjects	18	9	223
Age Categorical			
Units: Subjects			
<65 years	3	5	108
65 - <75 years	8	2	80
75 - <85 years	6	2	32
>= 85 years	1	0	3
Age Continuous			
The reporting group of "Phase 2: All Cohorts Combined" was a combination of all Phase 2 subjects. No analysis of this combined group was planned, therefore "0" was added.			
Units: years			
arithmetic mean	71.56	63.00	
standard deviation	± 7.37	± 10.91	-
Sex: Female, Male			
Units: Subjects			
Female	0	3	106
Male	18	6	117
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	0	7
Not Hispanic or Latino	16	8	198
Not reported	1	1	18
Race/Ethnicity, Customized			
Units: Subjects			
Black or African American	2	0	14
American Indian or Alaska Native	0	0	1
Asian	2	0	15
Native Hawaiian or Other Pacific Islander	0	0	1
White	14	9	179
Not reported	0	0	13
Geographic Region			
Units: Subjects			
North America	11	8	124
Western Europe	4	1	27
Eastern Europe	1	0	52
Australasia	1	0	10
Asia	1	0	10
ECOG Performance Status			
ECOG=Eastern Cooperative Oncology Group. Score 0=Fully active, able to carry on all pre-disease activities without restriction; 1=Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work or office work.			
Units: Subjects			
ECOG Score = 0	6	1	78
ECOG Score = 1	12	8	145

End points

End points reporting groups

Reporting group title	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD
Reporting group description: Subjects with locally advanced or metastatic solid tumors were treated with talazoparib 1.0 mg orally once daily (QD) in combination with avelumab 800 mg intravenously (IV) every 2 weeks (Q2W) for a maximum of 246.3 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort A1 (NSCLC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic non-small cell lung cancer (NSCLC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 183.6 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort A2 (NSCLC DDR+)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic NSCLC with DNA damage repair positive (DDR+) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 173.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort B1 (TNBC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or triple-negative breast cancer (TNBC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 93.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 180.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort C1 (OVC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic ovarian cancer (OVC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 161.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort C2 (OVC BRCA-mutated)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic OVC with germline or somatic BRCA1 or BRCA2 gene defect were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 144.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort D (UC)
Reporting group description: Subjects with locally advanced (primary or recurrent) or metastatic urothelial cancer (UC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 164.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort E1 (mCRPC)
Reporting group description: Subjects with metastatic castration-resistant prostate cancer (mCRPC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 54.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	

Reporting group title	Phase 2: Cohort E2 (mCRPC DDR+)
Reporting group description:	
Subjects with mCRPC with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 74.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Phase 2: Cohort F (BRCA/ATM-mutated)
Reporting group description:	
Subjects with locally advanced (primary or recurrent) or metastatic solid tumors, independent of tissue of origin, with previously identified pathogenic, or likely pathogenic, germline or somatic defects in BRCA1, BRCA2, or ATM genes were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 49.9 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Subject analysis set title	Avelumab PK Concentration Analysis Set
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Subjects from Phase 1b and Phase 2 combined (excluding site 1055). Treatment = Avelumab 800 mg IV Infusion Q2W coadministered with Talazoparib 1 mg QD. This analysis set is for PK analysis only, and not applicable for baseline characteristics.	
Subject analysis set title	Talazoparib PK Concentration Analysis Set (1 mg QD)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Subjects from Phase 1b and Phase 2 combined (excluding site 1055). Treatment = Avelumab 800 mg IV Infusion Q2W coadministered with Talazoparib 1 mg QD (subjects with normal renal function or mild renal impairment). This analysis set is for PK analysis only, and not applicable for baseline characteristics.	
Subject analysis set title	Talazoparib PK Concentration Analysis Set (0.75 mg QD)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Subjects from Phase 1b and Phase 2 combined (excluding site 1055). Treatment = Avelumab 800 mg IV Infusion Q2W coadministered with Talazoparib 0.75 mg QD (subjects with moderate renal impairment). This analysis set is for PK analysis only, and not applicable for baseline characteristics.	
Subject analysis set title	Phase 2 All Cohorts Combined
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
All subjects from Cohort A to Cohort F combined. Not applicable for baseline characteristics.	

Primary: Phase 1b: Number of Subjects with Dose Limiting Toxicities (DLTs)

End point title	Phase 1b: Number of Subjects with Dose Limiting Toxicities (DLTs) ^{[1][2]}
End point description:	
DLTs=any of the following adverse events (AEs) due to any study treatment in Cycle 1:Hematologic: grade(G)4 neutropenia >5 days (absolute neutrophil count [ANC]<0.5*10 ⁹ /L);febrile neutropenia;neutropenic infection (ANC<1.0*10 ⁹ /L and G>3 infection); G>=3 thrombocytopenia (platelet count [PC] <50.0*10 ⁹ /L) with bleeding; G4 thrombocytopenia (PC<25.0*10 ⁹ /L); G4 anemia (life-threatening;urgent intervention indicated). Non-hematologic: G>=3 toxicities unless predefined in the protocol; potential Hy's law cases. Non-adherence to treatment schedule: failure to deliver >=75% of the planned doses of talazoparib during Cycle 1 due to treatment-related toxicities;G3 non-hematologic toxicity that delayed either study drug for >=2 weeks. Dose reductions: any AE resulting in talazoparib dose reduction. The DLT analysis set included all eligible enrolled subjects in Phase 1b with >=1 dose of the combination who experienced DLT in Cycle 1 or completed the DLT	
End point type	Primary
End point timeframe:	
Cycle 1; 28 days	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this end point.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the

baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Subjects	3			

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment

End point title	Phase 2: Percentage of Subjects With Confirmed Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment ^[3] ^[4]
-----------------	--

End point description:

This outcome measure (OM) is reported for subjects with solid tumors except mCRPC; for those subjects, OR was defined as a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version(v) 1.1 by investigator. CR: Complete disappearance of all target and non-target lesions with the exception of nodal disease; all target and non-target nodes must decrease to normal size (short axis <10 mm); all lesions must be assessed. PR: $\geq 30\%$ decrease under baseline of the sum of diameters of all target measurable lesions; all target lesions must be assessed. Non-target PR lesions must be non-progressive disease (PD), where PD is unequivocal progression of pre-existing lesions. The full analysis set (FAS) included all enrolled subjects who received ≥ 1 dose of study treatment. Data for this OM was not planned to be collected and analyzed for Phase 1b arm. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this end point.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Percentage of Subjects				
number (confidence interval 95%)	16.7 (7.0 to 31.4)	20.0 (0.5 to 71.6)	18.2 (5.2 to 40.3)	34.8 (16.4 to 57.3)

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort F (BRCA/ATM- mutated)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	7
Units: Percentage of Subjects				
number (confidence interval 95%)	20.0 (5.7 to 43.7)	63.6 (30.8 to 89.1)	15.0 (5.7 to 29.8)	0 (0.0 to 41.0)

Statistical analyses

No statistical analyses for this end point

Primary: Phase 2: Percentage of Subjects With Confirmed Objective Response (OR) as per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment

End point title	Phase 2: Percentage of Subjects With Confirmed Objective Response (OR) as per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment ^{[5][6]}
-----------------	--

End point description:

This OM is reported for subjects with mCRPC; for those subjects, OR was defined as the proportion of subjects with a best overall soft tissue response of CR or PR per RECIST v1.1 and with no evidence of confirmed bone disease progression per PCWG3 criteria by investigator. CR: Complete disappearance of all target and non-target lesions with the exception of nodal disease; all target and non-target nodes must decrease to normal size (short axis <10 mm); all lesions must be assessed. PR: $\geq 30\%$ decrease under baseline of the sum of diameters of all target measurable lesions; all target lesions must be assessed. Non-target PR lesions must be non-PD. The full analysis set (FAS) included all enrolled subjects who received ≥ 1 dose of study treatment. Data for this OM was not planned to be collected and analyzed for Phase 1b arm. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Primary
----------------	---------

End point timeframe:

From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were planned for this end point.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort E1 (mCRPC)	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	18	2	
Units: Percentage of Subjects				
number (confidence interval 95%)	0 (0.0 to 16.1)	11.1 (1.4 to 34.7)	50.0 (1.3 to 98.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Treatment-Emergent Adverse Events (TEAEs)

End point title	Number of Subjects with Treatment-Emergent Adverse Events (TEAEs) ^[7]
-----------------	--

End point description:

Adverse event (AE) was any untoward medical occurrence in a subject who received any study drug without regard to possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Treatment-related AEs were those related to any study drug (ie, at least one of the study drugs). The safety analysis set included all enrolled subjects who received ≥ 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
Subjects with all-causality TEAEs	12	207		
Subjects with treatment-related TEAEs	11	197		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Serious TEAEs

End point title	Number of Subjects with Serious TEAEs ^[8]
-----------------	--

End point description:

TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Treatment-related AEs were those related to any study drug (ie, at least one of the study drugs). A serious TEAE was any untoward medical occurrence that at any dose resulted in any of following outcomes/considered to be an important medical event: death;life-threatening experience (immediate risk of death);required inpatient

hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect. The safety analysis set included all enrolled subjects who received ≥ 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
End point timeframe:	
From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)	

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
Subjects with all-causality serious TEAEs	1	75		
Subjects with treatment-related serious TEAEs	1	25		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with TEAEs Leading to Discontinuation of Either Study Drug

End point title	Number of Subjects with TEAEs Leading to Discontinuation of Either Study Drug ^[9]
-----------------	--

End point description:

Either study drug = avelumab only or talazoparib only. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Treatment-related (TR) AEs were those related to any study drug (ie, at least one of the study drugs). AC=all-causality. No.=Number of subjects. d/c=discontinuation. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
End point timeframe:	
From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)	

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
No. with AC TEAEs leading to d/c of avelumab	0	5		
No. with TR TEAEs leading to d/c of avelumab	0	4		
No. with AC TEAEs leading to d/c of talazoparib	1	9		
No. with TR TEAEs leading to d/c of talazoparib	1	8		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Grade ≥ 3 TEAEs

End point title	Number of Subjects with Grade ≥ 3 TEAEs ^[10]
-----------------	--

End point description:

AE was any untoward medical occurrence in a subject who received any study drug regardless of possibility of causal relationship. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. TEAEs were graded by the investigator using National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v4.03 as Grade(G) 1=mild; G2 =moderate; G3=severe; G4=life-threatening; G5=death. In this outcome measure, number of subjects with G3 or higher TEAEs were reported. Treatment-related AEs were those related to any study drug (ie, at least one of the study drugs). The safety analysis set included all enrolled subjects who received ≥ 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
Subjects with all-causality Grade ≥ 3 TEAEs	9	156		
Subjects with treatment-related Grade ≥ 3 TEAEs	9	120		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with TEAEs Leading to Death

End point title	Number of Subjects with TEAEs Leading to Death ^[11]
-----------------	--

End point description:

TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. No.=Number of subjects. Either study drug = avelumab only or talazoparib only. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Treatment-related (TR) AEs were those related to any study drug (ie, at least one of the study drugs). AC=all-causality. No.=Number of subjects. d/c=discontinuation. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
No. with all-causality TEAEs leading to death	0	21		
No. with treatment-related TEAEs leading to death	0	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with TEAEs Leading to Discontinuation of All Study Drugs

End point title	Number of Subjects with TEAEs Leading to Discontinuation of All Study Drugs ^[12]
-----------------	---

End point description:

All study drugs = all study drugs in the combination. TEAEs were those events with onset dates occurring during the on-treatment period. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. Treatment-related (TR) AEs were those related to any study drug (ie, at least one of the study drugs). AC=all-causality. No.=Number of subjects. d/c=discontinuation. Either study drug = avelumab only or talazoparib only. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
No.with AC TEAEs leading to d/c of all study drugs	1	20		
No.with TR TEAEs leading to d/c of all study drugs	0	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with New or Worsening Hematology Laboratory Test Results to Grade ≥ 3 During the On-Treatment Period

End point title	Number of Subjects with New or Worsening Hematology Laboratory Test Results to Grade ≥ 3 During the On-Treatment Period ^[13]
-----------------	--

End point description:

The number of subjects with newly occurring or worsening hematology abnormalities during the on-treatment period were summarized by worst grade on-treatment. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. NCI-CTCAE criteria version 4.03 is used. As per NCI CTCAE toxicity grading v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. N=x, y in the following table represents the number of evaluable subjects in the reporting groups of Phase 1b and Phase 2. APTT=Activated partial thromboplastin time. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
APTT prolonged (N=11, 143)	0	1		
Anemia (N=12, 208)	4	78		
Lymphocyte count decreased (N=12, 208)	4	44		
Neutrophil count decreased (N=12, 208)	5	27		
Platelet count decreased (N=12, 208)	4	47		
White blood cell decreased (N=12, 208)	3	20		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with New or Worsening Hematology Laboratory Test Results to Grade ≥ 1 During the On-Treatment Period

End point title	Number of Subjects with New or Worsening Hematology Laboratory Test Results to Grade ≥ 1 During the On-Treatment Period ^[14]
-----------------	--

End point description:

The number of subjects with newly occurring or worsening hematology abnormalities during the on-treatment period were summarized by worst grade on-treatment. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. NCI-CTCAE criteria version 4.03 is used. As per NCI CTCAE toxicity grading v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. N=x, y in the following table represents the number of evaluable subjects in the reporting groups of Phase 1b and Phase 2. APTT=Activated partial thromboplastin time. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
APTT prolonged (N=11, 143)	4	21		
Anemia (N=12, 208)	8	161		
Hemoglobin increased (N=12, 208)	0	1		
Lymphocyte count decreased (N=12, 208)	9	145		
Lymphocyte count increased (N=12, 208)	1	3		
Neutrophil count decreased (N=12, 208)	8	100		
Platelet count decreased (N=12, 208)	6	141		
White blood cell decreased (N=12, 208)	10	139		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with New or Worsening Chemistry Laboratory Test Results to Grade ≥ 1 During the On-Treatment Period

End point title	Number of Subjects with New or Worsening Chemistry Laboratory Test Results to Grade ≥ 1 During the On-Treatment Period ^[15]
-----------------	---

End point description:

The number of subjects with newly occurring or worsening chemistry abnormalities during the on-treatment period were summarized by worst grade on-treatment. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. NCI-CTCAE criteria version 4.03 is used. As per NCI CTCAE toxicity grading v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. N=x, y in the following table represents the number of evaluable subjects in the reporting groups of Phase 1b and Phase 2. CPK=Creatinine phosphokinase. GGT=Gamma-glutamyl transferase. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
Alanine aminotransferase increased (N=12, 208)	1	41		
Alkaline phosphatase increased (N=12, 208)	3	74		
Aspartate aminotransferase increased (N=12, 208)	2	53		
Blood bilirubin increased (N=12, 208)	0	24		
CPK increased (N=12, 206)	2	37		
Creatinine increased (N=12, 208)	9	147		
GGT increased (N=12, 206)	2	69		
Hypercalcemia (N=12, 208)	1	23		
Hyperglycemia (N=12, 208)	0	48		
Hyperkalemia (N=12, 208)	2	25		
Hypermagnesemia (N=12, 207)	0	21		
Hyponatremia (N=12, 208)	0	9		
Hypoalbuminemia (N=12, 208)	2	60		
Hypocalcemia (N=12, 208)	1	45		
Hypoglycemia (N=12, 208)	0	13		
Hypokalemia (N=12, 208)	3	36		
Hypomagnesemia (N=12, 207)	2	33		
Hyponatremia (N=12, 208)	4	66		
Hypophosphatemia (N=12, 206)	2	43		
Lipase increased (N=12, 207)	4	36		
Serum amylase increased (N=12, 207)	2	32		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with New or Worsening Chemistry Laboratory Test Results to Grade ≥ 3 During the On-Treatment Period

End point title	Number of Subjects with New or Worsening Chemistry Laboratory Test Results to Grade ≥ 3 During the On-Treatment Period ^[16]
-----------------	---

End point description:

The number of subjects with newly occurring or worsening chemistry abnormalities during the on-treatment period were summarized by worst grade on-treatment. On-treatment period was defined as time from first dose of any study treatment and up to 30 days after last dose or start day of new anti-cancer drug therapy minus 1 day, whichever occurred first. NCI-CTCAE criteria version 4.03 is used. As per NCI CTCAE toxicity grading v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death. N=x, y in the following table represents the number of evaluable subjects in the reporting groups of Phase 1b and Phase 2. CPK=Creatinine phosphokinase. GGT=Gamma-glutamyl transferase. The safety analysis set included all enrolled subjects who received at least 1 dose of study drug. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment up to 30 days after last dose or start of new anticancer therapy minus 1 day, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
Alanine aminotransferase increased (N=12, 208)	0	2		
Alkaline phosphatase increased (N=12, 208)	0	7		
Aspartate aminotransferase increased (N=12, 208)	0	2		
Blood bilirubin increased (N=12, 208)	0	3		
CPK increased (N=12, 206)	0	4		
Creatinine increased (N=12, 208)	0	2		
GGT increased (N=12, 206)	0	11		
Hyperglycemia (N=12, 208)	0	6		
Hyperkalemia (N=12, 208)	0	1		
Hypermagnesemia (N=12, 207)	0	5		
Hypoalbuminemia (N=12, 208)	0	2		
Hypocalcemia (N=12, 208)	0	4		
Hypokalemia (N=12, 208)	0	1		
Hyponatremia (N=12, 208)	0	12		
Hypophosphatemia (N=12, 206)	1	6		
Lipase increased (N=12, 207)	0	14		
Serum amylase increased (N=12, 207)	0	7		

Statistical analyses

No statistical analyses for this end point

Secondary: Trough concentrations (C_{trough})/Predose and maximum concentrations (C_{max}) of Serum Avelumab Concentrations (µg/mL) by Visit (Excluding Site 1055)

End point title	Trough concentrations (C _{trough})/Predose and maximum concentrations (C _{max}) of Serum Avelumab Concentrations (µg/mL) by Visit (Excluding Site 1055)
-----------------	---

End point description:

Pharmacokinetics (PK) data analyses included descriptive summary statistics of the pre-dose/C_{trough} concentrations for both investigational products and post-dose (for talazoparib) or C_{max} concentrations (for avelumab) for each cycle. N=x represents the number of evaluable subjects in each analysis set. "99999"=not available/applicable; for Cycle 1 Day 1, the result was not available as no observations were above the avelumab lower limit of quantitation (LLQ) of 0.2 µg/mL; for Cycle 24 results, only 1 subject was evaluable for the timepoints, so coefficient of variation is not applicable. The PK concentration analysis sets (1 unique set for each study drug used in the combination) were subsets of

the safety analysis set including subjects who had ≥ 1 post-dose concentration measurement above the LLQ for avelumab or talazoparib. Cohorts were combined as pre-specified in reporting and analysis plan. Site 1055 was excluded as samples were not meeting the protocol requirements.

End point type	Secondary
End point timeframe:	
Predose/0 Hour (H) and 1 H on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2-4, and additionally on Day 1 of Cycles 6, 9, 12, 18, and 24	

End point values	Avelumab PK Concentration Analysis Set			
Subject group type	Subject analysis set			
Number of subjects analysed	194			
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 / Day 1 (0 Hour [H]) (N=194)	99999 (± 99999)			
Cycle 1 / Day 1 (1 H) (N=178)	221.0 (± 41)			
Cycle 1 / Day 15 (0 H) (N=183)	21.20 (± 72)			
Cycle 1 / Day 15 (1 H) (N=164)	206.6 (± 86)			
Cycle 2 / Day 1 (0 H) (N=168)	26.41 (± 68)			
Cycle 2 / Day 1 (1 H) (N=156)	199.6 (± 110)			
Cycle 3 / Day 1 (0 H) (N=120)	31.45 (± 80)			
Cycle 3 / Day 1 (1 H) (N=126)	188.8 (± 105)			
Cycle 4 / Day 1 (0 H) (N=106)	34.59 (± 81)			
Cycle 4 / Day 1 (1 H) (N=114)	190.6 (± 99)			
Cycle 6 / Day 1 (0 H) (N=78)	37.40 (± 73)			
Cycle 6 / Day 1 (1 H) (N=81)	185.9 (± 98)			
Cycle 9 / Day 1 (0 H) (N=40)	39.97 (± 91)			
Cycle 9 / Day 1 (1 H) (N=44)	171.1 (± 145)			
Cycle 12 / Day 1 (0 H) (N=18)	47.10 (± 63)			
Cycle 12 / Day 1 (1 H) (N=18)	202.9 (± 88)			
Cycle 18 / Day 1 (0 H) (N=3)	53.94 (± 33)			
Cycle 18 / Day 1 (1 H) (N=3)	135.6 (± 354)			
Cycle 24 / Day 1 (0 H) (N=1)	76.40 (± 99999)			
Cycle 24 / Day 1 (1 H) (N=1)	378.0 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Predose and Postdose Plasma Talazoparib Concentrations (pg/mL) by Visit (Excluding Site 1055)

End point title	Predose and Postdose Plasma Talazoparib Concentrations (pg/mL) by Visit (Excluding Site 1055)
-----------------	---

End point description:

PK data analyses included descriptive summary statistics of the pre-dose/Ctrough concentrations for

both investigational products and post-dose (for talazoparib) or Cmax concentrations (for avelumab) for each cycle. Cmax/Ctrough = maximum/trough concentration. Subjects with moderate renal impairment were started at a lower, 0.75 mg QD, dose to compensate for decreased talazoparib clearance. N=x, y represents the number of evaluable subjects in each analysis set. "99999"=not available/applicable; for Cycle 1 Day 1, the result was not available as no observations were above the avelumab LLQ of 25 pg/mL. The PK concentration analysis sets (1 unique set for each study drug in the combination) were subsets of the safety analysis set including subjects who had ≥ 1 post-dose concentration measurement above the LLQ for avelumab or talazoparib. Cohorts were combined as pre-specified in reporting and analysis plan. Site 1055 was excluded as samples were not meeting the protocol requirements.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose and post-dose (at the end of the avelumab infusion) on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2-4.

End point values	Talazoparib PK Concentration Analysis Set (1 mg QD)	Talazoparib PK Concentration Analysis Set (0.75 mg QD)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	163	31		
Units: pg/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 / Day 1 (Predose) (N=163, 31)	99999 (\pm 99999)	99999 (\pm 99999)		
Cycle 1 / Day 1 (Postdose) (N=46, 12)	2295 (\pm 137)	2015 (\pm 112)		
Cycle 1 / Day 15 (Predose) (N=72, 10)	4672 (\pm 63)	4657 (\pm 47)		
Cycle 1 / Day 15 (Postdose) (N=33, 3)	9055 (\pm 88)	8257 (\pm 11)		
Cycle 2 / Day 1 (Predose) (N=66, 10)	4385 (\pm 53)	5871 (\pm 53)		
Cycle 2 / Day 1 (Postdose) (N=21, 5)	8479 (\pm 73)	9834 (\pm 62)		
Cycle 3 / Day 1 (Predose) (N=47, 6)	4212 (\pm 46)	3874 (\pm 48)		
Cycle 3 / Day 1 (Postdose) (N=22, 3)	6765 (\pm 239)	1236 (\pm 8074)		
Cycle 4 / Day 1 (Predose) (N=22, 3)	4713 (\pm 38)	3826 (\pm 73)		
Cycle 4 / Day 1 (Postdose) (N=29, 6)	6506 (\pm 76)	6735 (\pm 70)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With at Least 1 Valid Anti-drug Antibody (ADA) Result at: Any Time Point (N0), Baseline (N1), Baseline and Post-Baseline (N2), and Post-Baseline and Without Positive Baseline ADA Result (N3)

End point title	Number of Subjects With at Least 1 Valid Anti-drug Antibody (ADA) Result at: Any Time Point (N0), Baseline (N1), Baseline and Post-Baseline (N2), and Post-Baseline and Without Positive Baseline ADA Result (N3) ^[17]
-----------------	---

End point description:

Immunogenicity blood samples were assayed for ADA using a validated assay. The sample analysis followed a tiered approach of screening, confirmation, and titer determination. Samples tested positive for ADA were further analyzed for neutralizing antibodies (Nab) using a validated assay. Baseline was defined as the last assessment prior to the date/time of the first dose of avelumab. N0, N1, N2, and N3=Number of subjects with at least 1 valid ADA result at any time point, baseline (pre-dose on Day 1),

baseline and post-baseline, and post-baseline, respectively. The immunogenicity analysis set was a subset of the safety analysis set and included subjects who had at least 1 ADA/Nab sample collected for avelumab. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (within 2 hours of talazoparib dose) on Day 1 and Day 15 of Cycle 1, on Day 1 of Cycle 2-4 and then on Day 1 of Cycles 6, 9, 12, 18, 24, and at the end of treatment (EOT)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
N0	12	211		
N1	12	209		
N2	11	202		
N3	11	200		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects by ADA Categories

End point title	Number of Subjects by ADA Categories ^[18]
-----------------	--

End point description:

Immunogenicity blood samples were assayed for ADA using a validated assay. The sample analysis followed a tiered approach of screening, confirmation, and titer determination. Samples tested positive for ADA were further analyzed for neutralizing antibodies (Nab) using a validated assay. Baseline was defined as the last assessment prior to the date/time of the first dose of avelumab. N0, N1, N2, and N3=Number of subjects with at least 1 valid ADA result at any time point, baseline (pre-dose on Day 1), baseline and post-baseline, and post-baseline, respectively. n=number of subjects in each category. The immunogenicity analysis set was a subset of the safety analysis set and included subjects who had at least 1 ADA/Nab sample collected for avelumab. Cohorts in Phase 2 were combined as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (within 2 hours of talazoparib dose) on Day 1 and Day 15 of Cycles 1, on Day 1 of Cycle 2-4 and then on Day 1 of Cycles 6, 9, 12, 18, 24, and at the end of treatment (EOT)

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Phase 2 All Cohorts Combined		
Subject group type	Reporting group	Subject analysis set		
Number of subjects analysed	12	211		
Units: Subjects				
ADA never-positive (n/N0)	12	205		
ADA ever-positive (n/N0)	0	6		
ADA ever-positive (n/N1)	0	4		
ADA ever-positive (n/N2)	0	0		
ADA ever-positive (n/N3)	0	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: TTR in Subjects with Confirmed CR or PR

End point title	Phase 2: TTR in Subjects with Confirmed CR or PR ^[19]
-----------------	--

End point description:

For subjects with solid tumors except mCRPC, TTR was defined for subjects with confirmed OR (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response. For subjects with mCRPC, TTR was defined as the time from the first dose of study treatment to the first objective evidence of soft tissue response with no evidence of confirmed bone disease progression on bone scan per PCWG3. Soft tissue response was defined as a best overall response (BOR) of CR or PR as assessed by Investigator using RECIST v1.1. The full analysis set (FAS) included all enrolled participants who received at least 1 dose of study treatment. Data for this OM was planned for Phase 2 only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment to the first documentation of objective tumor response/the first objective evidence of soft tissue response with no evidence of confirmed bone disease progression (<= 5.2 years approximately)

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	1	4	8
Units: Months				
median (full range (min-max))	3.7 (1.7 to 11.3)	1.8 (1.8 to 1.8)	1.8 (1.6 to 2.0)	1.9 (1.6 to 3.6)

End point values	Phase 2: Cohort C1	Phase 2: Cohort C2	Phase 2: Cohort D (UC)	Phase 2: Cohort E2
------------------	-----------------------	-----------------------	---------------------------	-----------------------

	(OVC)	(OVC BRCA-mutated)		(mCRPC DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	7	6	2
Units: Months				
median (full range (min-max))	3.6 (1.7 to 17.9)	1.7 (1.6 to 3.7)	2.1 (1.4 to 5.9)	5.5 (5.4 to 5.6)

End point values	Phase 2: Cohort F (BRCA/ATM-mutated)			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Months				
median (full range (min-max))	1.8 (1.8 to 1.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Time to Response (TTR) in Subjects with Confirmed CR or PR

End point title	Phase 1b: Time to Response (TTR) in Subjects with Confirmed CR or PR ^[20]
-----------------	--

End point description:

For subjects with solid tumors except mCRPC, TTR was defined for subjects with confirmed OR (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response. For subjects with mCRPC, TTR was defined as the time from the first dose of study treatment to the first objective evidence of soft tissue response with no evidence of confirmed bone disease progression on bone scan per PCWG3. Soft tissue response was defined as a best overall response (BOR) of CR or PR as assessed by Investigator using RECIST v1.1. The FAS included all enrolled participants who received at least 1 dose of study treatment. Data for this OM was planned for Phase 1b arm only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment to the first documentation of objective tumor response/the first objective evidence of soft tissue response with no evidence of confirmed bone disease progression (<=5.2 years approximately)

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	2			
Units: Months				
median (full range (min-max))	1.8 (1.8 to 1.8)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Percentage of Subjects With Confirmed OR as per RECIST v1.1 and PCWG3 by Investigator Assessment

End point title	Phase 1b: Percentage of Subjects With Confirmed OR as per RECIST v1.1 and PCWG3 by Investigator Assessment ^[21]
-----------------	--

End point description:

This OM is reported for subjects in Phase 1b; OR was defined as the proportion of subjects with a best overall soft tissue response of CR or PR per RECIST v1.1 and with no evidence of confirmed bone disease progression per Prostate Cancer Working Group 3 (PCWG3) criteria by investigator. CR: Complete disappearance of all target and non-target lesions with the exception of nodal disease; all target and non-target nodes must decrease to normal size (short axis <10 mm); all lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions; all target lesions must be assessed. Non-target PR lesions must be non-PD. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Phase 1b arm only.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of the treatment until disease progression or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Percentage of Subjects				
number (confidence interval 95%)	16.7 (2.1 to 48.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Duration of Response (DR) in Subjects with Confirmed CR or PR

End point title	Phase 2: Duration of Response (DR) in Subjects with Confirmed CR or PR ^[22]
-----------------	--

End point description:

For subjects with solid tumors except mCRPC, DR was defined for subjects with confirmed OR (CR or PR)

as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. "99999"=Not applicable: Median and 95% CI were not estimated for <10 subjects. The full analysis set (FAS) included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Phase 2 only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure; Cohorts without evaluable subjects for this outcome measure [i.e., Phase 2: Cohort A2 (NSCLC DDR+), Phase 2: Cohort E1 (mCRPC), Phase 2: Cohort E2 (mCRPC DDR+), Phase 2: Cohort F (BRCA/ATM-mutated)] are not presented.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first objective tumor response/soft tissue response to the first objective tumor progression/subsequent objective evidence of radiographic progression or death due to any cause, whichever occurred first (<=5.2 years approximately)

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2-DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	1	4	8
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA-mutated)	Phase 2: Cohort D (UC)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	7	6	
Units: Months				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: PFS in Subjects with Confirmed CR or PR (RECIST v1.1 and PCWG3)

End point title	Phase 2: PFS in Subjects with Confirmed CR or PR (RECIST v1.1 and PCWG3) ^[23]
-----------------	--

End point description:

This OM was reported for subjects with mCRPC; for these subjects, PFS was defined as the time from the first dose of study treatment to documentation of radiographic progression in soft tissue as assessed by Investigator using RECIST v1.1, in bone as assessed by Investigator using PCWG3, or death, whichever occurred first. "99999"= Upper limit of 95% CI was not reached due to fewer number of subjects with event. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Phase 2 only. Here 'number of subjects analyzed' signifies

subjects evaluable for this outcome measure.

End point type	Secondary
End point timeframe:	
From the first dose of study treatment to the date of disease progression/radiographic progression in soft tissue or bone, or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)	

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort E1 (mCRPC)	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	18	2	
Units: Months				
median (confidence interval 95%)	4.1 (1.9 to 99999)	4.6 (1.7 to 9.8)	8.4 (5.9 to 10.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Progression-Free Survival (PFS) in Subjects with Confirmed CR or PR

End point title	Phase 1b: Progression-Free Survival (PFS) in Subjects with Confirmed CR or PR ^[24]
-----------------	---

End point description:

For subjects with solid tumors except mCRPC, PFS was defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurred first. For subjects with mCRPC, PFS was defined as the time from the first dose of study treatment to documentation of radiographic progression in soft tissue as assessed by Investigator using RECIST v1.1, in bone as assessed by Investigator using PCWG3, or death, whichever occurred first. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Phase 1b only.

End point type	Secondary
End point timeframe:	
From the first dose of study treatment to the date of disease progression/radiographic progression in soft tissue or bone, or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)	

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Months				
median (confidence interval 95%)	6.0 (1.8 to 11.5)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: PFS in Subjects with Confirmed CR or PR (RECIST v1.1)

End point title	Phase 2: PFS in Subjects with Confirmed CR or PR (RECIST v1.1) ^[25]
-----------------	--

End point description:

This OM is reported for subjects with solid tumors except mCRPC; for those subjects, PFS was defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurred first. "99999"= Upper limit of 95% CI was not reached due to fewer number of subjects with event. The full analysis set (FAS) included all enrolled participants who received at least 1 dose of study treatment. Data for this OM was planned for Phase 2 only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment to the date of disease progression/radiographic progression in soft tissue or bone, or death due to any cause, whichever occurred first (maximum up to 5.2 years approximately)

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Months				
median (confidence interval 95%)	4.7 (3.7 to 7.4)	1.9 (1.8 to 99999)	3.6 (1.9 to 5.6)	5.3 (2.0 to 12.8)

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort F (BRCA/ATM- mutated)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	7
Units: Months				

median (confidence interval 95%)	7.2 (4.0 to 9.1)	16.8 (7.2 to 99999)	3.6 (1.9 to 5.4)	1.7 (1.4 to 3.3)
----------------------------------	------------------	---------------------	------------------	------------------

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Overall Survival

End point title	Phase 1b: Overall Survival ^[26]
-----------------	--

End point description:

Overall survival (OS) was defined as the time from the first dose of study treatment to the date of death. Subjects without an event (death) were censored at the date of last contact. "99999"= Upper limit of 95% CI was not reached due to fewer number of subjects with event. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was for Phase 1b only.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment to the date of death (maximum up to 5.2 years approximately)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: Months				
median (confidence interval 95%)	18.5 (6.4 to 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Time to Prostate-Specific Antigen (PSA) Progression for Subjects with mCRPC

End point title	Phase 2: Time to Prostate-Specific Antigen (PSA) Progression for Subjects with mCRPC ^[27]
-----------------	--

End point description:

Time to PSA progression for subjects with mCRPC was defined as the time from the first dose to the date that a $\geq 25\%$ increase in PSA with an absolute increase of $\geq 2 \mu\text{g/L}$ (2 ng/mL) above the nadir (or baseline for subjects with no PSA decline) was documented, confirmed by a second consecutive PSA value obtained ≥ 3 weeks (21 days) later. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Phase 2 only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose to the date that a $\geq 25\%$ increase in PSA with an absolute increase of $\geq 2 \mu\text{g/L}$ (2 ng/mL) above the nadir (or baseline for subjects with no PSA decline) was documented (maximum up to 5.2 years approximately)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort E1 (mCRPC)	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	21	18	2	
Units: Months				
median (confidence interval 95%)	1.0 (1.0 to 4.6)	2.8 (1.0 to 6.5)	3.1 (1.6 to 4.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Overall Survival

End point title	Phase 2: Overall Survival ^[28]
-----------------	---

End point description:

OS was defined as the time from the first dose of study treatment to the date of death. Subjects without an event (death) were censored at the date of last contact. "99999"=Upper limit of 95% CI was not reached due to fewer number of subjects with event. The full analysis set (FAS) included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was for Phase 2 only.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose of study treatment to the date of death (maximum up to 5.2 years approximately)

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Months				
median (confidence interval 95%)	11.6 (8.4 to 14.9)	26.3 (3.5 to 43.3)	8.2 (5.8 to 13.0)	27.5 (12.6 to 40.2)

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA-)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
------------------	--------------------------------	--------------------------------------	---------------------------	----------------------------------

		mutated)		
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	21
Units: Months				
median (confidence interval 95%)	22.9 (7.8 to 99999)	38.8 (16.9 to 99999)	13.1 (8.5 to 19.2)	15.9 (9.6 to 20.7)

End point values	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	9		
Units: Months				
median (confidence interval 95%)	16.1 (10.8 to 23.4)	6.9 (1.4 to 27.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Percentage of Subjects With PSA Response

End point title	Phase 2: Percentage of Subjects With PSA Response ^[29]
-----------------	---

End point description:

PSA response was defined as the proportion of subjects with confirmed PSA decline $\geq 50\%$ compared to baseline. PSA response was calculated as a decline from baseline PSA (ng/mL) to the maximal PSA response with a threshold of 50%. A PSA response must be confirmed by a second consecutive value at least 3 weeks later. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was planned for Cohorts E1, E2, and F in Phase 2 only as pre-specified in reporting and analysis plan. Cohorts without evaluable subjects for this outcome measure [ie, Phase 2: Cohort F (BRCA/ATM-mutated)] are not presented.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline PSA (ng/mL) to the maximal PSA response with a threshold of 50% (maximum up to 5.2 years approximately)

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort E1 (mCRPC)	Phase 2: Cohort E2 (mCRPC DDR+)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	21	18		
Units: Percentage of Subjects				
number (confidence interval 95%)	9.5 (1.2 to 30.4)	5.6 (0.1 to 27.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 1b: Percentage of Subjects With CA-125 Response

End point title	Phase 1b: Percentage of Subjects With CA-125 Response ^[30]
-----------------	---

End point description:

Cancer Antigen 125 (CA-125) response is defined as at least a 50% reduction in CA-125 levels from baseline. The response must be confirmed and maintained for at least 28 days. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was for Phase 1b only. Here 'number of subjects analyzed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to at least a 50% reduction in CA-125 level (maximum up to 5.2 years approximately)

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 1b: Avelumab 800 mg Q2W + Talazoparib 1 mg QD			
Subject group type	Reporting group			
Number of subjects analysed	1			
Units: Percentage of Subjects				
number (confidence interval 95%)	100 (2.5 to 100.0)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Different Programmed Death-Ligand 1 (PD-L1) Status at Baseline

End point title	Number of Subjects With Different Programmed Death-Ligand 1 (PD-L1) Status at Baseline ^[31]
-----------------	--

End point description:

PD-L1 expression on tumor and infiltrating immune cells were measured by immunohistochemistry (IHC). PD-L1 expression level corresponds to the percentage of positive cells. The PD-L1 Positive category does not apply to cohorts A1 and A2. The PD-L1 High/Low categories only apply to cohorts A1 and A2. Subjects were considered positive if their baseline tumor tissue sample demonstrated cell surface PD-L1 expression: 1) for Cohorts E1, E2, and F: $\geq 1\%$ tumor cells (TC) or $\geq 5\%$ immune cells (IC); 2) for Cohort D: $TC/IC \geq 25\%$; 3) for Cohorts B1, B2, C1, C2: $IC \geq 5\%$; otherwise were considered negative. Categories based on PD-L1 expression level $\geq 50\%$ and $< 50\%$ were defined as High and Low, respectively. The full analysis set (FAS) included all enrolled subjects who received at

least 1 dose of study treatment. Data for this outcome measure was presented for Phase 2 only as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

At baseline (the last available assessment prior to the start of study treatment was defined as 'baseline' value or 'baseline' assessment)

Notes:

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Subjects				
High	3	1	0	0
Low	8	1	0	0
Positive (Not applicable for Cohorts A1 and A2)	0	0	8	3
Negative	22	2	6	16
Unknown	9	1	8	4

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	21
Units: Subjects				
High	0	0	0	0
Low	0	0	0	0
Positive (Not applicable for Cohorts A1 and A2)	5	5	13	1
Negative	13	4	19	13
Unknown	2	2	8	7

End point values	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	9		
Units: Subjects				
High	0	0		
Low	0	0		
Positive (Not applicable for Cohorts A1 and A2)	2	0		

Negative	12	3		
Unknown	4	6		

Statistical analyses

No statistical analyses for this end point

Secondary: Phase 2: Percentage of Subjects With CA-125 Response

End point title	Phase 2: Percentage of Subjects With CA-125 Response ^[32]
-----------------	--

End point description:

CA-125 response is defined as at least a 50% reduction in CA-125 levels from baseline. The response must be confirmed and maintained for at least 28 days. The FAS included all enrolled subjects who received at least 1 dose of study treatment. Data for this OM was for Cohorts C1 and C2 in Phase 2 only as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to at least a 50% reduction in CA-125 level (maximum up to 5.2 years approximately)

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	11		
Units: Percentage of Subjects				
number (confidence interval 95%)	45.0 (23.1 to 68.5)	63.6 (30.8 to 89.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Different Tumor Mutational Burden (TMB) at Baseline

End point title	Number of Subjects With Different Tumor Mutational Burden (TMB) at Baseline ^[33]
-----------------	---

End point description:

TMB was defined as the total number of mutations in the tumor genome, or number of mutations per megabase of DNA if derived from targeted sequencing. High: TMB score ≥ 20 muts/mb (number of mutations per megabase of DNA); Medium: TMB score ≥ 10 muts/mb and < 20 muts/mb; Low: TMB score < 10 muts/mb. The full analysis set (FAS) included all enrolled subjects who received at least 1 dose of study treatment. Data for this outcome measure was presented for Phase 2 only as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

At baseline (the last available assessment prior to the start of study treatment was defined as 'baseline' value or 'baseline' assessment)

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Subjects				
High	4	1	0	0
Medium	9	1	3	2
Low	13	3	12	20
Unknown	16	0	7	1

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	21
Units: Subjects				
High	0	0	5	0
Medium	1	2	4	0
Low	12	6	22	11
Unknown	7	3	9	10

End point values	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	9		
Units: Subjects				
High	2	0		
Medium	0	0		
Low	13	8		
Unknown	3	1		

Statistical analyses

Secondary: Number of Subjects With Different DNA Damage Repair (DDR) Status at Baseline

End point title	Number of Subjects With Different DNA Damage Repair (DDR) Status at Baseline ^[34]
-----------------	--

End point description:

DDR defect positive was determined by presence of one or more pathogenic or likely pathogenic mutations in tissue, DNA and/or blood samples. The full analysis set (FAS) included all enrolled subjects who received at least 1 dose of study treatment. Data for this outcome measure was presented for Phase 2 only as pre-specified in reporting and analysis plan.

End point type	Secondary
----------------	-----------

End point timeframe:

At baseline

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The endpoint is reporting statistics for the arms specified.

End point values	Phase 2: Cohort A1 (NSCLC)	Phase 2: Cohort A2 (NSCLC DDR+)	Phase 2: Cohort B1 (TNBC)	Phase 2: Cohort B2 (BC HR+ HER2- DDR+)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	42	5	22	23
Units: Subjects				
Positive	12	3	10	19
Negative	30	2	12	4
Unknown	0	0	0	0

End point values	Phase 2: Cohort C1 (OVC)	Phase 2: Cohort C2 (OVC BRCA- mutated)	Phase 2: Cohort D (UC)	Phase 2: Cohort E1 (mCRPC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	20	11	40	21
Units: Subjects				
Positive	5	10	18	7
Negative	15	1	22	13
Unknown	0	0	0	1

End point values	Phase 2: Cohort E2 (mCRPC DDR+)	Phase 2: Cohort F (BRCA/ATM- mutated)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	9		
Units: Subjects				
Positive	16	8		
Negative	2	1		

Unknown	0	0		
---------	---	---	--	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality: From start of the treatment (A) up to 90 days post last dose of study treatment (B), TEAEs and Serious TEAEs: From A up to 30 days post B or start of new anti-cancer drug therapy -1 day, whichever came first (\leq about 5.2 years)

Adverse event reporting additional description:

Same event may appear as both an AE and SAE. However, what is presented are distinct events. Safety set (all subjects who received at least 1 dose of study drug) was evaluated. An event may be categorized as serious in one subject and as non-serious in another, or a subject may have experienced both a serious and non-serious event.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.1

Reporting groups

Reporting group title	Cohort A1 (NSCLC)
-----------------------	-------------------

Reporting group description:

Subjects with locally advanced (primary or recurrent) or metastatic non-small cell lung cancer (NSCLC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 183.6 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Avelumab 800 mg Q2W + Talazoparib 1 mg QD
-----------------------	---

Reporting group description:

Subjects with locally advanced or metastatic solid tumors were treated with talazoparib 1.0 mg orally once daily (QD) in combination with avelumab 800 mg intravenously (IV) every 2 weeks (Q2W) for a maximum of 246.3 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Cohort B1 (TNBC)
-----------------------	------------------

Reporting group description:

Subjects with locally advanced (primary or recurrent) or triple-negative breast cancer (TNBC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 93.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Cohort A2 (NSCLC DDR+)
-----------------------	------------------------

Reporting group description:

Subjects with locally advanced (primary or recurrent) or metastatic NSCLC with DNA damage repair positive (DDR+) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 173.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Cohort E1 (mCRPC)
-----------------------	-------------------

Reporting group description:

Subjects with metastatic castration-resistant prostate cancer (mCRPC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 54.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Cohort E2 (mCRPC DDR+)
-----------------------	------------------------

Reporting group description:

Subjects with mCRPC with DDR+ were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 74.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.

Reporting group title	Cohort D (UC)
-----------------------	---------------

Reporting group description:

Subjects with locally advanced (primary or recurrent) or metastatic urothelial cancer (UC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 164.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of

new anticancer treatment, whichever comes first.

Reporting group title	Cohort C2 (OVC BRCA-mutated)
Reporting group description:	
Subjects with locally advanced (primary or recurrent) or metastatic OVC with germline or somatic BRCA1 or BRCA2 gene defect were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 144.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Cohort F (BRCA/ATM-mutated)
Reporting group description:	
Subjects with locally advanced (primary or recurrent) or metastatic solid tumors, independent of tissue of origin, with previously identified pathogenic, or likely pathogenic, germline or somatic defects in BRCA1, BRCA2, or ATM genes were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 49.9 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Cohort B2 (BC HR+ HER2- DDR+)
Reporting group description:	
Subjects with locally advanced (primary or recurrent) or triple-negative breast cancer (TNBC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 93.0 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	
Reporting group title	Cohort C1 (OVC)
Reporting group description:	
Subjects with locally advanced (primary or recurrent) or metastatic ovarian cancer (OVC) were treated with talazoparib 1 mg QD orally in combination with avelumab 800 mg IV Q2W for a maximum of 161.1 weeks. Safety follow-up was for 90 days after last dose of study treatment or until time of initiation of new anticancer treatment, whichever comes first.	

Serious adverse events	Cohort A1 (NSCLC)	Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Cohort B1 (TNBC)
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 42 (38.10%)	1 / 12 (8.33%)	7 / 22 (31.82%)
number of deaths (all causes)	33	6	16
number of deaths resulting from adverse events	3	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm progression			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			

subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suprapubic pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vaginal haemorrhage			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory distress			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			

subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyphaema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			

Atrial thrombosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	3 / 22 (13.64%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Anuria			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage urinary tract			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Glucocorticoid deficiency			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coccydynia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort A2 (NSCLC DDR+)	Cohort E1 (mCRPC)	Cohort E2 (mCRPC DDR+)
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)	5 / 21 (23.81%)	9 / 18 (50.00%)
number of deaths (all causes)	3	16	14
number of deaths resulting from adverse events	0	1	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm progression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Face oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suprapubic pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			

Female genital tract fistula			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Dyspnoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	2 / 18 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyphaema			

subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Dizziness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Constipation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Anuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage urinary tract			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Glucocorticoid deficiency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coccydynia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cellulitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort D (UC)	Cohort C2 (OVC BRCA-mutated)	Cohort F (BRCA/ATM-mutated)
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 40 (40.00%)	2 / 11 (18.18%)	4 / 9 (44.44%)
number of deaths (all causes)	26	6	7
number of deaths resulting from adverse events	3	1	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm progression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			

subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Circulatory collapse			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suprapubic pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			

subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			

subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural			

complications			
Accidental overdose			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyphaema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial thrombosis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac failure			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiopulmonary failure			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 40 (7.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neutropenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune thrombocytopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Anuria			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	4 / 40 (10.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage urinary tract			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Glucocorticoid deficiency			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Coccydynia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 40 (5.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			

Hyperglycaemia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort B2 (BC HR+ HER2- DDR+)	Cohort C1 (OVC)	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 23 (21.74%)	9 / 20 (45.00%)	
number of deaths (all causes)	16	11	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Malignant neoplasm progression			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm progression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Embolism			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Circulatory collapse			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	1 / 23 (4.35%)	2 / 20 (10.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suprapubic pain			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Female genital tract fistula			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Testicular pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vaginal haemorrhage			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyphaema			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haemorrhage			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial thrombosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Myocarditis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 23 (8.70%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune neutropenia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Immune thrombocytopenia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Melaena			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Anuria			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage urinary tract			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Glucocorticoid deficiency			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis of jaw			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coccydynia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Urinary tract infection			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cohort A1 (NSCLC)	Avelumab 800 mg Q2W + Talazoparib 1 mg QD	Cohort B1 (TNBC)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 42 (97.62%)	12 / 12 (100.00%)	21 / 22 (95.45%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Squamous cell carcinoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Basal cell carcinoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			

Haematoma			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	1	1	0
Hot flush			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	4	1	0
Hypertension			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	2
Hypotension			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	3 / 22 (13.64%)
occurrences (all)	2	0	3
Peripheral coldness			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	3
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	8 / 42 (19.05%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	13	0	2
Chest pain			

subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Fatigue			
subjects affected / exposed	17 / 42 (40.48%)	2 / 12 (16.67%)	8 / 22 (36.36%)
occurrences (all)	34	2	11
Facial pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	7 / 42 (16.67%)	5 / 12 (41.67%)	0 / 22 (0.00%)
occurrences (all)	8	5	0
Influenza like illness			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Localised oedema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	5 / 42 (11.90%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	8	0	3
Oedema peripheral			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	1
Peripheral swelling			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	7 / 42 (16.67%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	8	0	2
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Vulvovaginal dryness			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal pruritus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	17 / 42 (40.48%)	0 / 12 (0.00%)	9 / 22 (40.91%)
occurrences (all)	22	0	9
Dysphonia			
subjects affected / exposed	4 / 42 (9.52%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	4	0	0
Cough			
subjects affected / exposed	8 / 42 (19.05%)	1 / 12 (8.33%)	2 / 22 (9.09%)
occurrences (all)	12	1	2
Nasal congestion			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	2	1	0
Pharyngeal erythema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Productive cough			

subjects affected / exposed occurrences (all)	5 / 42 (11.90%) 8	0 / 12 (0.00%) 0	1 / 22 (4.55%) 1
Pulmonary embolism subjects affected / exposed occurrences (all)	3 / 42 (7.14%) 3	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Sinus congestion subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	2 / 22 (9.09%) 3
Confusional state subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 4	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Depressed mood subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Hallucination subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 12 (8.33%) 1	0 / 22 (0.00%) 0
Mood altered subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 2	0 / 12 (0.00%) 0	2 / 22 (9.09%) 2
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	3	0	1
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Amylase decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	3 / 42 (7.14%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	4	3	1
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	1	1	1
Blood albumin decreased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	9 / 42 (21.43%)	1 / 12 (8.33%)	3 / 22 (13.64%)
occurrences (all)	17	1	6
Blood bilirubin increased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Blood calcium decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	1
Blood creatinine increased			
subjects affected / exposed	1 / 42 (2.38%)	2 / 12 (16.67%)	2 / 22 (9.09%)
occurrences (all)	3	4	2
Blood lactate dehydrogenase increased			

subjects affected / exposed	4 / 42 (9.52%)	0 / 12 (0.00%)	3 / 22 (13.64%)
occurrences (all)	4	0	6
Blood magnesium decreased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	4	0	1
Blood uric acid increased			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Creatinine renal clearance decreased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	5	0	5
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Neutrophil count decreased			
subjects affected / exposed	2 / 42 (4.76%)	2 / 12 (16.67%)	1 / 22 (4.55%)
occurrences (all)	9	9	1
Lymphocyte count decreased			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	2 / 22 (9.09%)
occurrences (all)	5	1	6
Lipase increased			
subjects affected / exposed	4 / 42 (9.52%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	6	1	1
International normalised ratio increased			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	5 / 42 (11.90%)	0 / 12 (0.00%)	3 / 22 (13.64%)
occurrences (all)	12	0	3
Platelet count decreased			

subjects affected / exposed	3 / 42 (7.14%)	1 / 12 (8.33%)	4 / 22 (18.18%)
occurrences (all)	7	3	17
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	3	1	1
White blood cell count decreased			
subjects affected / exposed	1 / 42 (2.38%)	4 / 12 (33.33%)	1 / 22 (4.55%)
occurrences (all)	9	17	3
Weight increased			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	3	0	2
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Muscle injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	4 / 42 (9.52%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	4	1	1
Fall			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Soft tissue injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Spinal fracture			

subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Congenital, familial and genetic disorders			
Hypophosphatasia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	1	0	3
Atrial fibrillation			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	3
Palpitations			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	8 / 42 (19.05%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	9	0	1
Disturbance in attention			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	2	0	0
Headache			
subjects affected / exposed	7 / 42 (16.67%)	0 / 12 (0.00%)	4 / 22 (18.18%)
occurrences (all)	10	0	5
Dysgeusia			
subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	3 / 22 (13.64%)
occurrences (all)	2	0	5
Neuropathy peripheral			
subjects affected / exposed	0 / 42 (0.00%)	2 / 12 (16.67%)	0 / 22 (0.00%)
occurrences (all)	0	2	0
Somnolence			

subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Spinal cord compression			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	28 / 42 (66.67%)	8 / 12 (66.67%)	18 / 22 (81.82%)
occurrences (all)	114	42	59
Leukopenia			
subjects affected / exposed	7 / 42 (16.67%)	0 / 12 (0.00%)	3 / 22 (13.64%)
occurrences (all)	21	0	16
Thrombocytopenia			
subjects affected / exposed	15 / 42 (35.71%)	5 / 12 (41.67%)	9 / 22 (40.91%)
occurrences (all)	66	40	30
Neutropenia			
subjects affected / exposed	10 / 42 (23.81%)	7 / 12 (58.33%)	6 / 22 (27.27%)
occurrences (all)	22	77	20
Lymphopenia			
subjects affected / exposed	5 / 42 (11.90%)	0 / 12 (0.00%)	4 / 22 (18.18%)
occurrences (all)	34	0	16
Lymphadenopathy			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Vertigo			

subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	2 / 22 (9.09%) 2
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	2 / 42 (4.76%) 3	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 12 (8.33%) 1	0 / 22 (0.00%) 0
Diplopia subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 12 (8.33%) 1	0 / 22 (0.00%) 0
Gastrointestinal disorders			
Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 8	0 / 12 (0.00%) 0	1 / 22 (4.55%) 1
Ascites subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	6 / 42 (14.29%) 13	1 / 12 (8.33%) 1	5 / 22 (22.73%) 6
Diarrhoea subjects affected / exposed occurrences (all)	8 / 42 (19.05%) 9	0 / 12 (0.00%) 0	2 / 22 (9.09%) 3
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 42 (0.00%) 0	1 / 12 (8.33%) 1	0 / 22 (0.00%) 0
Abdominal distension subjects affected / exposed occurrences (all)	1 / 42 (2.38%) 1	0 / 12 (0.00%) 0	0 / 22 (0.00%) 0
Abdominal pain			

subjects affected / exposed	2 / 42 (4.76%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	2	0	3
Dysphagia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Dry mouth			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	1	0	2
Flatulence			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Gastritis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed	14 / 42 (33.33%)	0 / 12 (0.00%)	10 / 22 (45.45%)
occurrences (all)	20	0	13
Proctalgia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Noninfective gingivitis			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	3	1	4
Subileus			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Tongue discolouration			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Tongue pigmentation			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	4 / 42 (9.52%)	0 / 12 (0.00%)	4 / 22 (18.18%)
occurrences (all)	6	0	5
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	3 / 22 (13.64%)
occurrences (all)	3	1	3
Ecchymosis			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Petechiae			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	2
Skin hyperpigmentation			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Rash maculo-papular			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Rash erythematous			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	2 / 22 (9.09%)
occurrences (all)	2	1	2
Pruritus			
subjects affected / exposed	5 / 42 (11.90%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	8	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Acute kidney injury			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0

Haematuria			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Hydronephrosis			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Nocturia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Glucocorticoid deficiency			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Immune-mediated hypothyroidism			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Hypothyroidism			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	2	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	6 / 42 (14.29%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	12	0	3
Muscular weakness			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	2
Bone pain			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	0	1	1
Back pain			
subjects affected / exposed	7 / 42 (16.67%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	10	0	2
Musculoskeletal chest pain			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	1	1	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Tendon disorder			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	5	0	0
Osteoporosis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Myositis			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	3	0	0
Infections and infestations			
Candida infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Balanitis candida			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	1	1	0
Nasopharyngitis			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	4	0	0
Lower respiratory tract infection			
subjects affected / exposed	3 / 42 (7.14%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	4	0	0
Localised infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	5 / 42 (11.90%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	5	0	2

Sinusitis			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	2
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	2 / 42 (4.76%)	1 / 12 (8.33%)	1 / 22 (4.55%)
occurrences (all)	5	1	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	1	0	1
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	3 / 42 (7.14%)	2 / 12 (16.67%)	1 / 22 (4.55%)
occurrences (all)	5	3	1
Hypercalcaemia			
subjects affected / exposed	1 / 42 (2.38%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	1	4	0
Dehydration			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	1	0	2
Decreased appetite			
subjects affected / exposed	18 / 42 (42.86%)	1 / 12 (8.33%)	4 / 22 (18.18%)
occurrences (all)	25	1	4
Hyperkalaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Hypoalbuminaemia			

subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	2 / 22 (9.09%)
occurrences (all)	0	0	3
Hypocalcaemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Hypokalaemia			
subjects affected / exposed	2 / 42 (4.76%)	2 / 12 (16.67%)	2 / 22 (9.09%)
occurrences (all)	5	6	2
Hyperuricaemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	4	0
Hypomagnesaemia			
subjects affected / exposed	0 / 42 (0.00%)	1 / 12 (8.33%)	0 / 22 (0.00%)
occurrences (all)	0	1	0
Hyponatraemia			
subjects affected / exposed	0 / 42 (0.00%)	0 / 12 (0.00%)	1 / 22 (4.55%)
occurrences (all)	0	0	1
Hypophosphataemia			
subjects affected / exposed	3 / 42 (7.14%)	2 / 12 (16.67%)	1 / 22 (4.55%)
occurrences (all)	6	12	2
Vitamin D deficiency			
subjects affected / exposed	1 / 42 (2.38%)	0 / 12 (0.00%)	0 / 22 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Cohort A2 (NSCLC DDR+)	Cohort E1 (mCRPC)	Cohort E2 (mCRPC DDR+)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	21 / 21 (100.00%)	16 / 18 (88.89%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Tumour pain			
subjects affected / exposed	1 / 5 (20.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Squamous cell carcinoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Basal cell carcinoma			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Embolism			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Deep vein thrombosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Hypotension			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Peripheral coldness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Lymphoedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Chest pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Fatigue			
subjects affected / exposed	4 / 5 (80.00%)	10 / 21 (47.62%)	5 / 18 (27.78%)
occurrences (all)	5	16	8
Facial pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Chills			
subjects affected / exposed	0 / 5 (0.00%)	3 / 21 (14.29%)	2 / 18 (11.11%)
occurrences (all)	0	3	2
Influenza like illness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Localised oedema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 5 (0.00%)	3 / 21 (14.29%)	2 / 18 (11.11%)
occurrences (all)	0	3	3
Peripheral swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	4 / 18 (22.22%)
occurrences (all)	0	3	5

Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Reproductive system and breast disorders Pelvic pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 21 (9.52%) 2	2 / 18 (11.11%) 2
Dysphonia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	4 / 18 (22.22%) 5
Nasal congestion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Pulmonary haemorrhage subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1

Pharyngeal erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Sinus congestion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Confusional state			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Depressed mood			
subjects affected / exposed	1 / 5 (20.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Depression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Insomnia			

subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 21 (9.52%) 2	1 / 18 (5.56%) 1
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 21 (9.52%) 4	0 / 18 (0.00%) 0
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	0 / 18 (0.00%) 0
Amylase decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Amylase increased subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 3	3 / 21 (14.29%) 8	2 / 18 (11.11%) 16
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	3 / 21 (14.29%) 8	1 / 18 (5.56%) 1
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	3 / 21 (14.29%) 7	2 / 18 (11.11%) 2
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 3	1 / 18 (5.56%) 2
Blood calcium decreased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 4	2 / 21 (9.52%) 4	0 / 18 (0.00%) 0
Blood creatinine increased			

subjects affected / exposed	0 / 5 (0.00%)	4 / 21 (19.05%)	3 / 18 (16.67%)
occurrences (all)	0	7	6
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Creatinine renal clearance decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	0 / 5 (0.00%)	3 / 21 (14.29%)	2 / 18 (11.11%)
occurrences (all)	0	5	3
Lymphocyte count decreased			
subjects affected / exposed	1 / 5 (20.00%)	4 / 21 (19.05%)	2 / 18 (11.11%)
occurrences (all)	3	7	8
Lipase increased			
subjects affected / exposed	1 / 5 (20.00%)	3 / 21 (14.29%)	1 / 18 (5.56%)
occurrences (all)	2	6	2
International normalised ratio increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			

subjects affected / exposed	1 / 5 (20.00%)	2 / 21 (9.52%)	2 / 18 (11.11%)
occurrences (all)	1	3	5
Platelet count decreased			
subjects affected / exposed	1 / 5 (20.00%)	8 / 21 (38.10%)	7 / 18 (38.89%)
occurrences (all)	1	12	12
SARS-CoV-2 test positive			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 5 (0.00%)	4 / 21 (19.05%)	5 / 18 (27.78%)
occurrences (all)	0	9	15
Weight increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Muscle injury			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Limb injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Infusion related reaction			
subjects affected / exposed	0 / 5 (0.00%)	4 / 21 (19.05%)	2 / 18 (11.11%)
occurrences (all)	0	5	2
Fall			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Soft tissue injury			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Spinal fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Congenital, familial and genetic disorders			
Hypophosphatasia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Atrial fibrillation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 5 (20.00%)	2 / 21 (9.52%)	3 / 18 (16.67%)
occurrences (all)	1	3	3
Disturbance in attention			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Headache			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	2 / 18 (11.11%)
occurrences (all)	0	2	3
Dysgeusia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			

subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Somnolence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Spinal cord compression			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Syncope			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Tremor			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 5 (80.00%)	15 / 21 (71.43%)	10 / 18 (55.56%)
occurrences (all)	12	51	33
Leukopenia			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Thrombocytopenia			
subjects affected / exposed	1 / 5 (20.00%)	6 / 21 (28.57%)	3 / 18 (16.67%)
occurrences (all)	3	19	4
Neutropenia			
subjects affected / exposed	2 / 5 (40.00%)	3 / 21 (14.29%)	0 / 18 (0.00%)
occurrences (all)	22	6	0
Lymphopenia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear congestion			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	0 / 18 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 2	0 / 18 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Diplopia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	0 / 18 (0.00%) 0
Gastrointestinal disorders Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Ascites subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	3 / 5 (60.00%) 3	5 / 21 (23.81%) 7	2 / 18 (11.11%) 4
Diarrhoea subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 2	4 / 21 (19.05%) 9	4 / 18 (22.22%) 6
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Abdominal distension			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Dysphagia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Flatulence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Lip swelling			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Lip dry			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 5 (0.00%)	8 / 21 (38.10%)	6 / 18 (33.33%)
occurrences (all)	0	8	11
Proctalgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Noninfective gingivitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Subileus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tongue discolouration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tongue pigmentation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)	6 / 21 (28.57%)	3 / 18 (16.67%)
occurrences (all)	0	7	4
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	2 / 18 (11.11%)
occurrences (all)	1	0	2
Ecchymosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Petechiae			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin ulcer			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Skin hyperpigmentation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	3 / 18 (16.67%)
occurrences (all)	0	0	5
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Acute kidney injury subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Hydronephrosis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Nocturia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Pollakiuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	1 / 18 (5.56%) 1
Proteinuria subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 3
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Immune-mediated hypothyroidism subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 21 (4.76%) 1	0 / 18 (0.00%) 0
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	4 / 18 (22.22%)
occurrences (all)	0	3	5
Muscular weakness			
subjects affected / exposed	0 / 5 (0.00%)	4 / 21 (19.05%)	0 / 18 (0.00%)
occurrences (all)	0	5	0
Muscle spasms			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	2 / 18 (11.11%)
occurrences (all)	0	2	2
Groin pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Flank pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Bone pain			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	1 / 5 (20.00%)	4 / 21 (19.05%)	2 / 18 (11.11%)
occurrences (all)	2	4	5
Musculoskeletal chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Tendon disorder			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	1 / 18 (5.56%)
occurrences (all)	0	5	2
Osteoporosis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0

Osteonecrosis of jaw subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	2 / 18 (11.11%) 2
Myositis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	2 / 18 (11.11%) 2
Infections and infestations			
Candida infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Balanitis candida subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 2
Cystitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 3	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Localised infection subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	1 / 18 (5.56%) 1
Herpes zoster subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0
Oral candidiasis			

subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 21 (4.76%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	4
Upper respiratory tract infection			
subjects affected / exposed	2 / 5 (40.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1
Skin infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	2 / 18 (11.11%)
occurrences (all)	0	3	6
Hypercalcaemia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 21 (4.76%)	1 / 18 (5.56%)
occurrences (all)	1	1	2
Dehydration			
subjects affected / exposed	0 / 5 (0.00%)	0 / 21 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	2 / 5 (40.00%)	5 / 21 (23.81%)	6 / 18 (33.33%)
occurrences (all)	2	7	6
Hyperkalaemia			
subjects affected / exposed	0 / 5 (0.00%)	2 / 21 (9.52%)	0 / 18 (0.00%)
occurrences (all)	0	4	0

Hypermagnesaemia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 21 (9.52%) 2	0 / 18 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 21 (9.52%) 3	2 / 18 (11.11%) 3
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 21 (9.52%) 4	2 / 18 (11.11%) 2
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 5	2 / 21 (9.52%) 3	2 / 18 (11.11%) 3
Hyperuricaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 21 (4.76%) 1	0 / 18 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 21 (0.00%) 0	3 / 18 (16.67%) 4
Hyponatraemia subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	1 / 21 (4.76%) 1	2 / 18 (11.11%) 5
Hypophosphataemia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 21 (9.52%) 4	2 / 18 (11.11%) 4
Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 21 (0.00%) 0	0 / 18 (0.00%) 0

Non-serious adverse events	Cohort D (UC)	Cohort C2 (OVC BRCA-mutated)	Cohort F (BRCA/ATM- mutated)
Total subjects affected by non-serious adverse events subjects affected / exposed	38 / 40 (95.00%)	10 / 11 (90.91%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Squamous cell carcinoma			

subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Basal cell carcinoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Flushing			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Embolism			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Deep vein thrombosis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	5	0
Hypotension			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Peripheral coldness			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Orthostatic hypotension			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lymphoedema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	8	0	0
Chest pain			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	14 / 40 (35.00%)	8 / 11 (72.73%)	6 / 9 (66.67%)
occurrences (all)	28	16	9
Facial pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	4 / 40 (10.00%)	2 / 11 (18.18%)	2 / 9 (22.22%)
occurrences (all)	4	2	2
Influenza like illness			
subjects affected / exposed	3 / 40 (7.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	3	0	1
Localised oedema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Mucosal inflammation			
subjects affected / exposed	2 / 40 (5.00%)	2 / 11 (18.18%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Non-cardiac chest pain			
subjects affected / exposed	3 / 40 (7.50%)	2 / 11 (18.18%)	0 / 9 (0.00%)
occurrences (all)	3	2	0
Oedema peripheral			
subjects affected / exposed	3 / 40 (7.50%)	2 / 11 (18.18%)	4 / 9 (44.44%)
occurrences (all)	3	2	6
Peripheral swelling			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Pyrexia			

subjects affected / exposed occurrences (all)	8 / 40 (20.00%) 9	3 / 11 (27.27%) 4	0 / 9 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Reproductive system and breast disorders Pelvic pain subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	8 / 40 (20.00%) 13	3 / 11 (27.27%) 5	2 / 9 (22.22%) 3
Dysphonia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	7 / 40 (17.50%) 8	3 / 11 (27.27%) 3	1 / 9 (11.11%) 1
Nasal congestion subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	2 / 11 (18.18%) 3	1 / 9 (11.11%) 1
Pulmonary haemorrhage subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Oropharyngeal pain			

subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Pharyngeal erythema			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 40 (0.00%)	2 / 11 (18.18%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Pulmonary embolism			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Sinus congestion			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Confusional state			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Depressed mood			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Restlessness			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Mood altered			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Insomnia subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 2	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 6	2 / 11 (18.18%) 3	1 / 9 (11.11%) 1
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	2 / 9 (22.22%) 2
Amylase decreased subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Amylase increased subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 4	1 / 11 (9.09%) 1	1 / 9 (11.11%) 2
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 2	2 / 11 (18.18%) 2	1 / 9 (11.11%) 2
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	4 / 40 (10.00%) 5	1 / 11 (9.09%) 1	3 / 9 (33.33%) 3
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	2 / 9 (22.22%) 4
Blood calcium decreased subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 2	2 / 11 (18.18%) 5	0 / 9 (0.00%) 0
Blood creatinine increased			

subjects affected / exposed	7 / 40 (17.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	14	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Blood magnesium decreased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Creatinine renal clearance decreased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Neutrophil count decreased			
subjects affected / exposed	5 / 40 (12.50%)	10 / 11 (90.91%)	1 / 9 (11.11%)
occurrences (all)	24	75	1
Lymphocyte count decreased			
subjects affected / exposed	3 / 40 (7.50%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	3	0	16
Lipase increased			
subjects affected / exposed	2 / 40 (5.00%)	1 / 11 (9.09%)	3 / 9 (33.33%)
occurrences (all)	4	1	6
International normalised ratio increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Gamma-glutamyltransferase increased			

subjects affected / exposed	3 / 40 (7.50%)	1 / 11 (9.09%)	4 / 9 (44.44%)
occurrences (all)	11	6	4
Platelet count decreased			
subjects affected / exposed	7 / 40 (17.50%)	7 / 11 (63.64%)	2 / 9 (22.22%)
occurrences (all)	24	38	3
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	1	4	2
White blood cell count decreased			
subjects affected / exposed	9 / 40 (22.50%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	35	23	1
Weight increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Muscle injury			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Infusion related reaction			
subjects affected / exposed	6 / 40 (15.00%)	1 / 11 (9.09%)	2 / 9 (22.22%)
occurrences (all)	6	1	2
Fall			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Soft tissue injury			

subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Spinal fracture subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Congenital, familial and genetic disorders Hypophosphatasia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 4	2 / 11 (18.18%) 2	1 / 9 (11.11%) 1
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Memory impairment subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Headache subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 4	4 / 11 (36.36%) 6	1 / 9 (11.11%) 1
Dysgeusia subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 3	5 / 11 (45.45%) 5	0 / 9 (0.00%) 0
Neuropathy peripheral			

subjects affected / exposed	0 / 40 (0.00%)	2 / 11 (18.18%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Somnolence			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Spinal cord compression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	31 / 40 (77.50%)	7 / 11 (63.64%)	5 / 9 (55.56%)
occurrences (all)	134	41	26
Leukopenia			
subjects affected / exposed	5 / 40 (12.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	9	0	0
Thrombocytopenia			
subjects affected / exposed	16 / 40 (40.00%)	4 / 11 (36.36%)	2 / 9 (22.22%)
occurrences (all)	50	8	9
Neutropenia			
subjects affected / exposed	6 / 40 (15.00%)	2 / 11 (18.18%)	2 / 9 (22.22%)
occurrences (all)	26	7	8
Lymphopenia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	12	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear congestion			

subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Vertigo subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Diplopia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Gastrointestinal disorders Abdominal pain lower subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Ascites subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	7 / 40 (17.50%) 12	4 / 11 (36.36%) 8	2 / 9 (22.22%) 2
Diarrhoea subjects affected / exposed occurrences (all)	7 / 40 (17.50%) 7	3 / 11 (27.27%) 8	3 / 9 (33.33%) 4
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Abdominal distension			

subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	2 / 9 (22.22%)
occurrences (all)	1	1	2
Abdominal pain			
subjects affected / exposed	1 / 40 (2.50%)	3 / 11 (27.27%)	3 / 9 (33.33%)
occurrences (all)	2	7	3
Dysphagia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 40 (2.50%)	3 / 11 (27.27%)	0 / 9 (0.00%)
occurrences (all)	1	6	0
Dry mouth			
subjects affected / exposed	2 / 40 (5.00%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	2	3	1
Flatulence			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gastritis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Gastroesophageal reflux disease			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lip swelling			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Lip dry			

subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	12 / 40 (30.00%)	6 / 11 (54.55%)	2 / 9 (22.22%)
occurrences (all)	12	10	2
Proctalgia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Oral pain			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Noninfective gingivitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 40 (0.00%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	0	6	1
Subileus			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Tongue discolouration			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Tongue pigmentation			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	2 / 40 (5.00%)	4 / 11 (36.36%)	2 / 9 (22.22%)
occurrences (all)	3	8	2
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	1 / 40 (2.50%)	3 / 11 (27.27%)	0 / 9 (0.00%)
occurrences (all)	3	3	0
Ecchymosis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	4
Night sweats			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Petechiae			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Skin ulcer			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Skin hyperpigmentation			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Rash erythematous			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	3 / 40 (7.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Pruritus			
subjects affected / exposed	3 / 40 (7.50%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	5	2	1
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Acute kidney injury subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 4	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Haematuria subjects affected / exposed occurrences (all)	6 / 40 (15.00%) 6	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Hydronephrosis subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Nocturia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Pollakiuria subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	1 / 9 (11.11%) 1
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Immune-mediated hypothyroidism subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 2	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	8 / 40 (20.00%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	9	4	1
Muscular weakness			
subjects affected / exposed	0 / 40 (0.00%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Muscle spasms			
subjects affected / exposed	1 / 40 (2.50%)	3 / 11 (27.27%)	1 / 9 (11.11%)
occurrences (all)	1	4	1
Groin pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Flank pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Bone pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	5 / 40 (12.50%)	2 / 11 (18.18%)	1 / 9 (11.11%)
occurrences (all)	5	2	1
Musculoskeletal chest pain			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	2	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Tendon disorder			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	3 / 40 (7.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Osteoporosis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0

Osteonecrosis of jaw subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Myositis subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	3 / 11 (27.27%) 3	0 / 9 (0.00%) 0
Infections and infestations			
Candida infection subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 2	0 / 9 (0.00%) 0
COVID-19 subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Balanitis candida subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Cystitis subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 11 (9.09%) 1	0 / 9 (0.00%) 0
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Localised infection subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Herpes zoster subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Oral candidiasis			

subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Pneumonia			
subjects affected / exposed	3 / 40 (7.50%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Sinusitis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Vulvovaginal mycotic infection			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	6 / 40 (15.00%)	1 / 11 (9.09%)	2 / 9 (22.22%)
occurrences (all)	9	4	2
Upper respiratory tract infection			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	0	1	1
Skin infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 11 (0.00%)	2 / 9 (22.22%)
occurrences (all)	4	0	5
Hypercalcaemia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 11 (9.09%)	1 / 9 (11.11%)
occurrences (all)	2	1	1
Dehydration			
subjects affected / exposed	0 / 40 (0.00%)	1 / 11 (9.09%)	3 / 9 (33.33%)
occurrences (all)	0	1	3
Decreased appetite			
subjects affected / exposed	5 / 40 (12.50%)	1 / 11 (9.09%)	4 / 9 (44.44%)
occurrences (all)	9	6	4
Hyperkalaemia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 11 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0

Hypermagnesaemia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	5 / 40 (12.50%) 7	0 / 11 (0.00%) 0	2 / 9 (22.22%) 4
Hypocalcaemia subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 5	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 4	1 / 11 (9.09%) 2	0 / 9 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 2	3 / 11 (27.27%) 3	0 / 9 (0.00%) 0
Hyponatraemia subjects affected / exposed occurrences (all)	4 / 40 (10.00%) 8	2 / 11 (18.18%) 6	2 / 9 (22.22%) 6
Hypophosphataemia subjects affected / exposed occurrences (all)	4 / 40 (10.00%) 5	0 / 11 (0.00%) 0	1 / 9 (11.11%) 1
Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 11 (0.00%) 0	0 / 9 (0.00%) 0

Non-serious adverse events	Cohort B2 (BC HR+ HER2- DDR+)	Cohort C1 (OVC)	
Total subjects affected by non-serious adverse events subjects affected / exposed	22 / 23 (95.65%)	20 / 20 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Squamous cell carcinoma			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Basal cell carcinoma			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Flushing			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Embolism			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Deep vein thrombosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Hot flush			
subjects affected / exposed	1 / 23 (4.35%)	2 / 20 (10.00%)	
occurrences (all)	1	2	
Hypertension			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Hypotension			
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)	
occurrences (all)	1	1	
Peripheral coldness			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Orthostatic hypotension			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Lymphoedema			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 23 (8.70%)	4 / 20 (20.00%)	
occurrences (all)	2	9	
Chest pain			
subjects affected / exposed	2 / 23 (8.70%)	0 / 20 (0.00%)	
occurrences (all)	3	0	
Fatigue			
subjects affected / exposed	10 / 23 (43.48%)	11 / 20 (55.00%)	
occurrences (all)	12	13	
Facial pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Chills			
subjects affected / exposed	4 / 23 (17.39%)	4 / 20 (20.00%)	
occurrences (all)	4	4	
Influenza like illness			
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)	
occurrences (all)	2	1	
Localised oedema			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Mucosal inflammation			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Oedema peripheral			
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)	
occurrences (all)	0	2	
Peripheral swelling			
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)	
occurrences (all)	1	2	
Pyrexia			

subjects affected / exposed occurrences (all)	4 / 23 (17.39%) 5	2 / 20 (10.00%) 2	
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 20 (5.00%) 1	
Reproductive system and breast disorders Pelvic pain subjects affected / exposed occurrences (all) Vulvovaginal dryness subjects affected / exposed occurrences (all) Vulvovaginal pruritus subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0 0 / 23 (0.00%) 0 0 / 23 (0.00%) 0	0 / 20 (0.00%) 0 0 / 20 (0.00%) 0 0 / 20 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all) Dysphonia subjects affected / exposed occurrences (all) Cough subjects affected / exposed occurrences (all) Nasal congestion subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all) Pulmonary haemorrhage subjects affected / exposed occurrences (all) Oropharyngeal pain	2 / 23 (8.70%) 2 1 / 23 (4.35%) 1 2 / 23 (8.70%) 2 2 / 23 (8.70%) 2 1 / 23 (4.35%) 1 0 / 23 (0.00%) 0 0	7 / 20 (35.00%) 11 1 / 20 (5.00%) 1 2 / 20 (10.00%) 6 1 / 20 (5.00%) 1 0 / 20 (0.00%) 0 0 / 20 (0.00%) 0	

subjects affected / exposed	1 / 23 (4.35%)	3 / 20 (15.00%)	
occurrences (all)	1	3	
Pharyngeal erythema			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Productive cough			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Pulmonary embolism			
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)	
occurrences (all)	0	3	
Sinus congestion			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)	
occurrences (all)	0	2	
Confusional state			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Depressed mood			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Depression			
subjects affected / exposed	2 / 23 (8.70%)	0 / 20 (0.00%)	
occurrences (all)	2	0	
Hallucination			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Restlessness			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Mood altered			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	

Insomnia subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 3	2 / 20 (10.00%) 2	
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 2	4 / 20 (20.00%) 8	
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Amylase decreased subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Amylase increased subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	3 / 20 (15.00%) 3	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 3	3 / 20 (15.00%) 5	
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	2 / 20 (10.00%) 3	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 4	3 / 20 (15.00%) 14	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	1 / 20 (5.00%) 3	
Blood calcium decreased subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 3	3 / 20 (15.00%) 7	
Blood creatinine increased			

subjects affected / exposed	0 / 23 (0.00%)	4 / 20 (20.00%)
occurrences (all)	0	9
Blood lactate dehydrogenase increased		
subjects affected / exposed	0 / 23 (0.00%)	4 / 20 (20.00%)
occurrences (all)	0	8
Blood magnesium decreased		
subjects affected / exposed	0 / 23 (0.00%)	4 / 20 (20.00%)
occurrences (all)	0	15
Blood urea increased		
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	18
Blood uric acid increased		
subjects affected / exposed	0 / 23 (0.00%)	3 / 20 (15.00%)
occurrences (all)	0	17
Creatinine renal clearance decreased		
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	4
Electrocardiogram QT prolonged		
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	1
Neutrophil count decreased		
subjects affected / exposed	3 / 23 (13.04%)	5 / 20 (25.00%)
occurrences (all)	20	21
Lymphocyte count decreased		
subjects affected / exposed	3 / 23 (13.04%)	3 / 20 (15.00%)
occurrences (all)	10	18
Lipase increased		
subjects affected / exposed	1 / 23 (4.35%)	4 / 20 (20.00%)
occurrences (all)	1	9
International normalised ratio increased		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Gamma-glutamyltransferase increased		

subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	3 / 20 (15.00%) 6	
Platelet count decreased subjects affected / exposed occurrences (all)	4 / 23 (17.39%) 11	5 / 20 (25.00%) 19	
SARS-CoV-2 test positive subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Weight decreased subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 20 (5.00%) 1	
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 10	4 / 20 (20.00%) 30	
Weight increased subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 20 (5.00%) 4	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 2	3 / 20 (15.00%) 3	
Muscle injury subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Limb injury subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Infusion related reaction subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	1 / 20 (5.00%) 1	
Fall subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 2	0 / 20 (0.00%) 0	
Soft tissue injury			

subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Spinal fracture subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Congenital, familial and genetic disorders Hypophosphatasia subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	2 / 20 (10.00%) 2	
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Palpitations subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 2	4 / 20 (20.00%) 9	
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Memory impairment subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	4 / 23 (17.39%) 5	2 / 20 (10.00%) 7	
Dysgeusia subjects affected / exposed occurrences (all)	2 / 23 (8.70%) 2	0 / 20 (0.00%) 0	
Neuropathy peripheral			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Somnolence			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Spinal cord compression			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Syncope			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Tremor			
subjects affected / exposed	1 / 23 (4.35%)	2 / 20 (10.00%)	
occurrences (all)	1	3	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	10 / 23 (43.48%)	12 / 20 (60.00%)	
occurrences (all)	29	77	
Leukopenia			
subjects affected / exposed	1 / 23 (4.35%)	4 / 20 (20.00%)	
occurrences (all)	1	13	
Thrombocytopenia			
subjects affected / exposed	2 / 23 (8.70%)	9 / 20 (45.00%)	
occurrences (all)	7	39	
Neutropenia			
subjects affected / exposed	4 / 23 (17.39%)	4 / 20 (20.00%)	
occurrences (all)	6	9	
Lymphopenia			
subjects affected / exposed	0 / 23 (0.00%)	5 / 20 (25.00%)	
occurrences (all)	0	33	
Lymphadenopathy			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Ear and labyrinth disorders			
Ear congestion			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Vertigo			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Ocular hyperaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Diplopia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Abdominal pain lower			
subjects affected / exposed	0 / 23 (0.00%)	3 / 20 (15.00%)	
occurrences (all)	0	3	
Abdominal pain upper			
subjects affected / exposed	1 / 23 (4.35%)	2 / 20 (10.00%)	
occurrences (all)	1	2	
Ascites			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Constipation			
subjects affected / exposed	4 / 23 (17.39%)	3 / 20 (15.00%)	
occurrences (all)	5	3	
Diarrhoea			
subjects affected / exposed	5 / 23 (21.74%)	7 / 20 (35.00%)	
occurrences (all)	6	10	
Abdominal discomfort			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Abdominal distension			

subjects affected / exposed	1 / 23 (4.35%)	5 / 20 (25.00%)
occurrences (all)	1	5
Abdominal pain		
subjects affected / exposed	2 / 23 (8.70%)	3 / 20 (15.00%)
occurrences (all)	2	3
Dysphagia		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Dyspepsia		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Dry mouth		
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)
occurrences (all)	1	0
Flatulence		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Gastritis		
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	1
Gastrointestinal pain		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Gastroesophageal reflux disease		
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	1
Gingival bleeding		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Mouth ulceration		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Lip swelling		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Lip dry		

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	11 / 23 (47.83%)	14 / 20 (70.00%)	
occurrences (all)	15	17	
Proctalgia			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Oral pain			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Noninfective gingivitis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Stomatitis			
subjects affected / exposed	3 / 23 (13.04%)	1 / 20 (5.00%)	
occurrences (all)	9	1	
Subileus			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Tongue discolouration			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Tongue pigmentation			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Vomiting			
subjects affected / exposed	6 / 23 (26.09%)	4 / 20 (20.00%)	
occurrences (all)	6	7	
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Alopecia			

subjects affected / exposed	3 / 23 (13.04%)	3 / 20 (15.00%)	
occurrences (all)	3	3	
Ecchymosis			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Erythema			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Night sweats			
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)	
occurrences (all)	1	1	
Petechiae			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Skin ulcer			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Skin hyperpigmentation			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Rash maculo-papular			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Rash erythematous			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)	
occurrences (all)	0	2	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	

Acute kidney injury subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Haematuria subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	2 / 20 (10.00%) 2	
Hydronephrosis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Nocturia subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Pollakiuria subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 20 (5.00%) 1	
Proteinuria subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Urinary incontinence subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	1 / 20 (5.00%) 1	
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	1 / 20 (5.00%) 1	
Glucocorticoid deficiency subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Immune-mediated hypothyroidism subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Hypothyroidism subjects affected / exposed occurrences (all)	3 / 23 (13.04%) 3	2 / 20 (10.00%) 2	
Musculoskeletal and connective tissue disorders			

Arthralgia		
subjects affected / exposed	6 / 23 (26.09%)	2 / 20 (10.00%)
occurrences (all)	6	2
Muscular weakness		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Muscle spasms		
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)
occurrences (all)	1	1
Groin pain		
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)
occurrences (all)	0	1
Flank pain		
subjects affected / exposed	2 / 23 (8.70%)	3 / 20 (15.00%)
occurrences (all)	3	4
Bone pain		
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)
occurrences (all)	1	1
Back pain		
subjects affected / exposed	8 / 23 (34.78%)	5 / 20 (25.00%)
occurrences (all)	11	6
Musculoskeletal chest pain		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Musculoskeletal discomfort		
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)
occurrences (all)	1	0
Tendon disorder		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0
Pain in extremity		
subjects affected / exposed	2 / 23 (8.70%)	4 / 20 (20.00%)
occurrences (all)	2	5
Osteoporosis		
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0

Osteonecrosis of jaw subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Myositis subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	1 / 20 (5.00%) 1	
Myalgia subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 3	1 / 20 (5.00%) 2	
Infections and infestations			
Candida infection subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
COVID-19 subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Balanitis candida subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Cystitis subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	0 / 20 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	1 / 20 (5.00%) 1	
Lower respiratory tract infection subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Localised infection subjects affected / exposed occurrences (all)	0 / 23 (0.00%) 0	0 / 20 (0.00%) 0	
Herpes zoster subjects affected / exposed occurrences (all)	1 / 23 (4.35%) 1	0 / 20 (0.00%) 0	
Oral candidiasis			

subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Pneumonia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Sinusitis			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 23 (4.35%)	1 / 20 (5.00%)	
occurrences (all)	1	2	
Urinary tract infection			
subjects affected / exposed	2 / 23 (8.70%)	1 / 20 (5.00%)	
occurrences (all)	2	1	
Upper respiratory tract infection			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Skin infection			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 23 (0.00%)	4 / 20 (20.00%)	
occurrences (all)	0	6	
Hypercalcaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Dehydration			
subjects affected / exposed	0 / 23 (0.00%)	2 / 20 (10.00%)	
occurrences (all)	0	2	
Decreased appetite			
subjects affected / exposed	3 / 23 (13.04%)	5 / 20 (25.00%)	
occurrences (all)	3	7	
Hyperkalaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	

Hypermagnesaemia			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	
Hypoalbuminaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Hypocalcaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Hypokalaemia			
subjects affected / exposed	2 / 23 (8.70%)	2 / 20 (10.00%)	
occurrences (all)	2	2	
Hyperuricaemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Hypomagnesaemia			
subjects affected / exposed	0 / 23 (0.00%)	3 / 20 (15.00%)	
occurrences (all)	0	8	
Hyponatraemia			
subjects affected / exposed	0 / 23 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Hypophosphataemia			
subjects affected / exposed	1 / 23 (4.35%)	0 / 20 (0.00%)	
occurrences (all)	6	0	
Vitamin D deficiency			
subjects affected / exposed	0 / 23 (0.00%)	0 / 20 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 November 2018	<ul style="list-style-type: none">• Human epidermal growth factor receptor 2 negative requirement was added to inclusion criterion for hormone receptor positive breast cancer patients for clarity.• Flexibility in the target number of patients to be enrolled in the Phase 2 cohorts of the study was added to avoid a dedicated protocol amendment in case additional data are needed in a specific biomarker defined population.• The Schedule of Activities was updated to clarify procedures for patients who continue treatment beyond 2 years (Cycles >25) to lessen study participation burden for long term study participants. Serum/urine pregnancy test procedures are no longer required at Day 60 and Day 90 of Short Term Follow Up (only Day 30).• Physical exams are permitted to be performed 1 day prior to the scheduled visit to confirm any findings before dosing.• Permissible highly effective methods of contraception were updated as per current protocol standard, including the addition of sexual abstinence.• DDR defect status assessment procedures were revised to allow prospective and local (where applicable) testing of DDR defects.• Preliminary safety data from the Phase 1b portion of this study were added to Benefit/Risk Assessment.• In response to queries raised by the Ministry of Food and Drug Safety of South Korea for sites in South Korea only, specific eligibility criteria were restricted for Cohorts A1, B1, and D.• A DDR gene list has been added inclusion criteria for Cohorts A2, B2, and E2, to better define the DDR defect positive status required for eligibility.• Requirements for tumor assessments for progressive disease confirmation were removed.• A separate withdrawal of consent form is not applicable to this study and was removed from procedures.• Activated partial thromboplastin time assessment was permitted as an alternative to partial thromboplastin time. Prothrombin time was removed.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported